Innovation Pharmaceuticals Inc. IPIX

Buster Bob,

Did you figure out that nitric vs nitrous oxide thing yet?

Chemistry is tough. Especially basic high school/undergrad chemistry...

Buster Bob is back! I was worried something happened to him...

Actually, Bob, the company has been a pretty terrible source of information...

I tend to read primary literature. I’m also trained to (one of those medical guys).

Did you go back and read about the difference between nitric and nitrous oxide (seriously, I’m going to dine out on this one for months!)

BusterBob

You know there’s a difference between Nitric Oxide (NO) (the vasodilator/flow impedance reducer) and Nitrous Oxide (N2O) (the gas you inhale before you post on this board)...

Glad we are reading advice on biotech from someone who failed undergrad biochemistry...

Vijay - remdesevir is not anywhere close to 99% effective. Where did you get this number. It has shown no mortality benefit, but does show a decrease in hospital length of stay.
Right now remdesevir is just the best thing we have to use - anything with mortality benefit will essentially replace remdesevir.

Likely clear benefit will be combination therapy.

Whether Brilacidin shows that benefit will only be apparent when they unblind the data. The suspicion is that they got that signal early on... hence adding sites and the fda interest...

I hate to disrupt the cult meeting Buster Bob and Chumbo are having this morning...

There was a press conference a few weeks back where Fauci talked about antivirals in trials, but stated “they are understandably reticent to discuss them publically” or something to that effect. It was soon after that fda added innovation to the verboten list for employees of fda... now that Merck/Ridgeback has all but canned molnupiravir, who is left for competition in the true antiviral category?

George Mason in vitro studies showing synergy have to be a set up for phase 3 trials to have a combo arm. Let’s see what Gilead does with this...

Russian study latest details - using google translate, it looks like they’ve enrolled 106.

We may be on a 29 day countdown to data already...

Reposted from Reddit - Crashco01 gets credit for finding this!

http://grls.rosminzdrav.ru/CiPermitionReg.aspx?PermYear=0&DateInc=&NumInc=&DateBeg=&DateEnd=&Protocol=IPI-BRIc-201&RegNm=&Statement=&ProtoId=&idCIStatementCh=&Qualifier=&CiPhase=&RangeOfApp=&Torg=&LFDos=&Producer=&Recearcher=&sponsorCountry=&MedBaseCount=&CiType=&PatientCount=&OrgDocOut=2&Status=1&NotInReg=0&All=0&PageSize=8&order=dateperm&orderType=desc&pagenum=1

Covid cases rising in Illinois (research site is suburban Chicago), Michigan (Detroit is 60 miles from the Toledo research site - Ohio/Michigan border), and there’s an uptick in Louisiana (Metairie research site is suburban NOLA).

Hopefully now that full 5-day dosing is authorized, we see enrollment complete this month (if cases only came from these three sites, excluding the dozen Russian sites, only one a day each from each site and enrollment would be full after 30 days).

Given the number of sites, the fact that they have data from 1/4 (meaning apparatus is up and running), I have to think as early as May is a reasonable time frame for completing the study.

Correction to last post: would Gilead (not Pfizer) be more likely to buyout Innovation or pay royalties to produce a combination therapy if synergistic with Brilacidin?

So would a Pfizer be more likely to straight up buyout the company if Bril is synergistic with remdesevir or pay royalties fir a combination therapy?